Publishers

Need unique free news content for your site customized to your audience?

Let's Discuss

PRESS RELEASE
By: InvestorBrandNetwork (IBN)
August 27, 2024

Annovis Bio (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), offered key business updates and announced financial results for the second quarter ended June 30, 2024. The company reported productive recent months, with encouraging data on lead compound buntanetap’s performance […]

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This press release is distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Annovis Bio (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement.

{site_meta && site_meta.display_name} Logo

InvestorBrandNetwork (IBN)

The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.